Pharmacotherapeutic follow-up of patients with gestational toxoplasmosis in primary health care

Abstract

Objective: To describe and analyze the application of pharmacotherapeutic follow-up services to pregnant women undergoing treatment for toxoplasmosis in primary health care. Methods: This is a descriptive, analytical, observational and cross-sectional study on pharmaceutical care for patients undergoing treatment for gestational toxoplasmosis in primary care in Fortaleza, Ceará, between August 2022 and July 2023. Data were obtained from the electronic medical record. Results: Consultations were held monthly from the first dispensation until the completion or suspension of treatment. During the research period, 149 pregnant women received medication for toxoplasmosis, of which 41 supported follow-up with the pharmacist. Of these, 68.3% were over 25 years old, 75.6% started monitoring in the 2nd trimester of pregnancy and 58.5% had some DRP, of which 49% were related to administration and/or adherence to treatment. Spiramycin was the most prescribed medication (78.5%). Among the interventions carried out (160), 85% were information and advice. Conclusion: Monitoring promotes guidance and adherence to treatment, case notification, identification and monitoring of DRPs, contributing to the strengthening of pharmaceutical care in primary care.